Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10381392 | 1.00 | PARP1 (0.50) | PARP1HSD11B1MTNR1AHTR2CHTR2B | |
| SCHEMBL4793712 | 0.95 | PARP1 (0.46) | PARP1HSD11B1MTNR1AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL5732143 | 0.93 | PARP1 (0.45) | PARP1HSD11B1MTNR1AHTR2CHTR2B | |
| SCHEMBL927341 | 0.89 | HSD11B1 (0.41) | HSD11B1MTNR1APNMT | |
| SCHEMBL31158955 | 0.89 | HSD11B1 (0.41) | HSD11B1MTNR1APNMT | |
| SCHEMBL4703624 | 0.82 | PRMT5 (0.40) | PARP1 | |
| SCHEMBL2878709 | 0.79 | PRMT5 (0.40) | PARP1 | |
| SCHEMBL11167058 | 0.79 | PARP1 (0.39) | PARP1 | |
| SCHEMBL1735335 | 0.78 | HTR2C (0.41) | PARP1HTR2CHTR2B | |
| SCHEMBL20777506 | 0.77 | ALDH1A1 (0.43) | MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136577-A1 | HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS | C4X DISCOVERY LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| EP-4472734-A1 | HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS | C4X Discovery Limited (GB) | 2024-12-11 | — | — | EP | disclosed |
| CN-119095837-A | Heterocyclic derivatives as MALT1 inhibitors | 希四克斯探索有限公司 | 2024-12-06 | — | — | CN | disclosed |
| WO-2023148501-A1 | HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS | C4X DISCOVERY LIMITED (GB) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136577-A1 | HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS | MALT1, SQSTM1, FKBP1A | PARP1 2244/4885HSD11B1 247/4885MTNR1A 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.